{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:41:29Z","timestamp":1785541289008,"version":"3.56.0"},"reference-count":34,"publisher":"Copernicus GmbH","issue":"3","license":[{"start":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T00:00:00Z","timestamp":1586649600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Bone Joint Infect."],"abstract":"<jats:p>Abstract. Introduction: Treatment of methicillin-resistant (MR) staphylococcal prosthetic joint infections (PJIs) remains a matter of discussion, with vancomycin-rifampin combination therapy being the preferred treatment for DAIR and one-stage exchange arthroplasty strategies. This study analyzes the outcomes of patients with chronic methicillin-resistant coagulase-negative staphylococcal PJIs treated with vancomycin-minocycline combination therapy.Methods: This prospective, single center cohort study included all chronic MR coagulase-negative staphylococcal PJIs (01\/2004-12\/2014) treated with exchange arthroplasty and at least 4 weeks of minocycline-vancomycin. The following endpoints were considered: reinfection including relapse (same microorganism) and a new infection (different microorganism) and PJI-related deaths. Their outcomes were compared with PJIs treated with rifampin-vancomycin during the same period.Results: Thirty-four patients (median age, 69 years) with 22 hip and 12 knee arthroplasty infections were included. Sixteen (47%) had previously been managed in another center. Median vancomycin MIC of strains was 3 mg\/L. Nineteen underwent one-stage, 15 two-stage exchange arthroplasty. After a median [IQR] follow-up of 43 [26-68] months, 2 patients relapsed and 6 developed a new PJI. Compared to 36 rifampin-vancomycin treated PJIs, relapse- or reinfection-free survival rates didn't differ, but more new infections developed in the minocycline group (6 vs 3; P 0.3).Conclusions: Minocycline-vancomycin combination therapy for chronic MR coagulase-negative staphylococcal PJIs seems to be an interesting therapeutic alternative.\n                    <\/jats:p>","DOI":"10.7150\/jbji.43254","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T06:55:14Z","timestamp":1587106514000},"page":"110-117","source":"Crossref","is-referenced-by-count":12,"title":["Minocycline Combined with Vancomycin for the Treatment of Methicillin-Resistant Coagulase-Negative Staphylococcal Prosthetic Joint Infection Managed with Exchange Arthroplasty"],"prefix":"10.5194","volume":"5","author":[{"given":"G\u00e9raldine","family":"Bart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Kerroumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Heym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Meyssonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Desplaces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Dominique","family":"Kitzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Ziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Marmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3145","published-online":{"date-parts":[[2020,4,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH. Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res. 2009;467:1732\u20131739. [PMC free article]","DOI":"10.1007\/s11999-009-0857-z"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Triffault-Fillit C, Ferry T, Laurent F. et al. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. Clin Microbiol Infection. 2019;25:353\u2013358.","DOI":"10.1016\/j.cmi.2018.04.035"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Zeller V, Kerroumi Y, Meyssonnier V. et al. Analysis of postoperative and haematogenous prosthetic joint infection microbiological patterns of in a large cohort. J Infect. 2018;76:328\u2013334.","DOI":"10.1016\/j.jinf.2017.12.016"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Osmon DR, Berbari EF, Berendt AR. et al. Executive summary: Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1\u201310.","DOI":"10.1093\/cid\/cis966"},{"key":"ref5","unstructured":"Ariza J, Cobo J, Baraia-Etxaburu J. et al. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) Enferm Infecc Microbiol Clin. 2017;35:189\u2013195."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Norden C. Lessons learned from animal models of osteomyelitis. Rev Infect Dis. 1988;10:103\u2013110.","DOI":"10.1093\/clinids\/10.1.103"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zimmerli W, Widmer A, Blatter M, Frei R, Ochsner P; for the FBI study group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA. 1998;279:1537\u20131541.","DOI":"10.1001\/jama.279.19.1537"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lora-Tamayo J, Murillo O, Iribarren JA. et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56:182\u2013194.","DOI":"10.1093\/cid\/cis746"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Tshefu K, Zimmerli W, Waldvogel FA. Short-term rifampin administration in the prevention or eradication of foreign body infection. Rev Infect Dis. 1983;(Suppl 3):S474\u2013S480.","DOI":"10.1093\/clinids\/5.Supplement_3.S474"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign-body infections. J Infect Dis. 1990;162:96\u2013102.","DOI":"10.1093\/infdis\/162.1.96"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Blaser J, Verg\u00e8res P, Widmer AF, Zimmerli W. In vivo verification of an in-vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother. 1995;39:1134\u20131139. [PMC free article]","DOI":"10.1128\/AAC.39.5.1134"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Diekema DJ, Pfaller MA, Schmitz FJ, et al; SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2):S114\u2013132.","DOI":"10.1086\/320184"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Zimmerli W. Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med. 2014;276:111\u2013119.","DOI":"10.1111\/joim.12233"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Dubee V, Zeller V, Lhotellier L. et al. Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a treatment of choice in the era of antimicrobial resistance. Clin Microbiol Infect. 2013;19:E98\u2013105.","DOI":"10.1111\/1469-0691.12071"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Trotti A, Colevas AD, Setser A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176\u2013181.","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zeller V, Lhotellier L, Marmor S. et al. One-stage exchange arthroplasty for prosthetic hip infection: long-term results of a large cohort study. J Bone Joint Surg Am. 2014;96(1):e1.. https:\/\/doi.org\/ 10.2106\/JBJS.L.01451.","DOI":"10.2106\/JBJS.L.01451"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampin-minocycline association. J Antimicrob Chemother. 1984;13(Suppl C):17\u201322.","DOI":"10.1093\/jac\/13.suppl_C.17"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis. 1998;26:1182\u20131187.","DOI":"10.1086\/520285"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40:1429\u20131434.","DOI":"10.1086\/429628"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cunha BA. Minocycline, often forgotten, but preferred to trimethoprim-sulfamethoxazole or doxycycline for the treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int J Antimicrob Agents. 2013;42:497\u2013499.","DOI":"10.1016\/j.ijantimicag.2013.08.006"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Raad I, Hanna H, Jiang Y. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656\u20131660. [PMC free article]","DOI":"10.1128\/AAC.00350-06"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Minuth JN, Holmes TM, Musher DM. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother. 1974;6:411\u2013414. [PMC free article]","DOI":"10.1128\/AAC.6.4.411"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Yuk JH, Dignani MC, Harris RL, Bradshaw MW, Williams TW. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis. 1991;13:1023\u20131024.","DOI":"10.1093\/clinids\/13.5.1023"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Speer B, Shoemaker N, Salyers A. Bacterial resistance to tetracycline: mechanism, transfer and clinical significance. Clin Microbiol Rev. 1992;5:387\u2013399. [PMC free article]","DOI":"10.1128\/CMR.5.4.387"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bishburg E, Bishburg K. Minocycline, an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34:395\u2013401.","DOI":"10.1016\/j.ijantimicag.2009.06.021"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rodvold KA, Gotfried MH, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221\u20131229.","DOI":"10.1093\/jac\/dkl403"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Bhattacharya I, Gotfried MH, Ji AJ. et al. Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. J Clin Pharmacol. 2014;54:70\u20134.","DOI":"10.1002\/jcph.201"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Vuagnat A, Stern R, Lotthe A. et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351\u2013357.","DOI":"10.1111\/j.1365-2710.2004.00572.x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F. Combination of minocycline and rifampin against methicillin- and gentamicin-resistant Staphylococcus aureus. J Clin Pathol. 1981;34:559\u2013563. [PMC free article]","DOI":"10.1136\/jcp.34.5.559"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Griffin A, Harting J, Christensen D. Tigecycline in the management of osteomyelitis: a case series from bone and joint infection (BAJIO) database. Diagn Microbiol Infect Dis. 2013;77:273\u2013277.","DOI":"10.1016\/j.diagmicrobio.2013.07.014"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wach J, Dinh A, Dutronc H. et al. Tigecycline-based prolonged salvage therapy in patients presenting with complex bone and joint infection. Med Mal Infect. 2018;48:53\u201357.","DOI":"10.1016\/j.medmal.2017.09.001"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Nguyen S, Robineau O, Titecat M. et al. Influence of daily dosage and frequency of administration of rifampin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infection. Eur J Clin Microbiol Infect Dis. 2015;34:1675\u20131682.","DOI":"10.1007\/s10096-015-2404-z"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Morata L, Senneville E, Bernard L. et al. A retrospective review of the clinical experience of linezolide with or without rifampin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther. 2014;3:235\u2013243. [PMC free article]","DOI":"10.1007\/s40121-014-0032-z"},{"key":"ref34","unstructured":"Legout L, Valette M, Dezeque H. et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampin on the occurrence of anaemia? J Antimicrob Chemother. 2010;65:2224\u20132230."}],"container-title":["Journal of Bone and Joint Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jbji.copernicus.org\/articles\/5\/110\/2020\/jbji-5-110-2020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T09:11:43Z","timestamp":1596532303000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbji.copernicus.org\/articles\/5\/110\/2020\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,12]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.7150\/jbji.43254","relation":{},"ISSN":["2206-3552"],"issn-type":[{"value":"2206-3552","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,12]]}}}